| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Circulating tumour DNA in patients with advanced melanoma treated with dabrafenib or dabrafenib plus trametinib: a clinical validation study
|
Syeda, Mahrukh M
|
|
|
22 |
3 |
p. 370-380
|
artikel
|
| 2 |
Circulating tumour DNA in patients with melanoma receiving targeted therapy
|
Forschner, Andrea
|
|
|
22 |
3 |
p. 291-293
|
artikel
|
| 3 |
Combination treatment options for small-cell lung cancer
|
Horita, Nobuyuki
|
|
|
22 |
3 |
p. e83
|
artikel
|
| 4 |
Combination treatment options for small-cell lung cancer – Authors' reply
|
Goldman, Jonathan W
|
|
|
22 |
3 |
p. e84
|
artikel
|
| 5 |
Comparison of breast cancer and cervical cancer stage distributions in ten newly independent states of the former Soviet Union: a population-based study
|
Ryzhov, Anton
|
|
|
22 |
3 |
p. 361-369
|
artikel
|
| 6 |
Correction to Lancet Oncol 2020; 21: 763–75
|
|
|
|
22 |
3 |
p. e92
|
artikel
|
| 7 |
Correction to Lancet Oncol 2021; 22: 198–211
|
|
|
|
22 |
3 |
p. e92
|
artikel
|
| 8 |
Current situation of oncology biosimilars in Japan
|
Nagai, Sumimasa
|
|
|
22 |
3 |
p. e82
|
artikel
|
| 9 |
Dramatic drop in new cancer drug trials during the COVID-19 pandemic
|
Wilkinson, Emma
|
|
|
22 |
3 |
p. 305
|
artikel
|
| 10 |
Endoscopic surgery compared with intensity-modulated radiotherapy in resectable locally recurrent nasopharyngeal carcinoma: a multicentre, open-label, randomised, controlled, phase 3 trial
|
Liu, You-Ping
|
|
|
22 |
3 |
p. 381-390
|
artikel
|
| 11 |
From periwinkle to an enduring anticancer drug
|
Faguet, Guy
|
|
|
22 |
3 |
p. 308
|
artikel
|
| 12 |
Global costs, health benefits, and economic benefits of scaling up treatment and imaging modalities for survival of 11 cancers: a simulation-based analysis
|
Ward, Zachary J
|
|
|
22 |
3 |
p. 341-350
|
artikel
|
| 13 |
4 Gy versus 24 Gy radiotherapy for follicular and marginal zone lymphoma (FoRT): long-term follow-up of a multicentre, randomised, phase 3, non-inferiority trial
|
Hoskin, Peter
|
|
|
22 |
3 |
p. 332-340
|
artikel
|
| 14 |
High-dose versus standard-dose twice-daily thoracic radiotherapy for patients with limited stage small-cell lung cancer: an open-label, randomised, phase 2 trial
|
Grønberg, Bjørn Henning
|
|
|
22 |
3 |
p. 321-331
|
artikel
|
| 15 |
Intermediate clinical endpoints for surrogacy in localised prostate cancer: an aggregate meta-analysis
|
Gharzai, Laila A
|
|
|
22 |
3 |
p. 402-410
|
artikel
|
| 16 |
Intermediate clinical endpoints in localised prostate cancer
|
Tree, Alison C
|
|
|
22 |
3 |
p. 294-296
|
artikel
|
| 17 |
Interpreting the RAPIDO trial: factors to consider
|
Yuval, Jonathan B
|
|
|
22 |
3 |
p. e87-e88
|
artikel
|
| 18 |
Interpreting the RAPIDO trial: factors to consider
|
Kumar, Naveena A N
|
|
|
22 |
3 |
p. e86
|
artikel
|
| 19 |
Interpreting the RAPIDO trial: factors to consider
|
Glynne-Jones, Rob
|
|
|
22 |
3 |
p. e85
|
artikel
|
| 20 |
Interpreting the RAPIDO trial: factors to consider
|
Pastorino, Alessandro
|
|
|
22 |
3 |
p. e89
|
artikel
|
| 21 |
Interpreting the RAPIDO trial: factors to consider – Authors' reply
|
Bahadoer, Renu R
|
|
|
22 |
3 |
p. e90-e91
|
artikel
|
| 22 |
Laparoscopic complete mesocolic excision: safe for right colon cancer?
|
Mathis, Kellie
|
|
|
22 |
3 |
p. 293-294
|
artikel
|
| 23 |
New action plan for palliative care in the UK
|
Das, Manjulika
|
|
|
22 |
3 |
p. 304
|
artikel
|
| 24 |
Pathological fracture from clinically occult breast cancer
|
Carrascosa, Miguel F
|
|
|
22 |
3 |
p. e131
|
artikel
|
| 25 |
Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trial
|
Xu, Binghe
|
|
|
22 |
3 |
p. 351-360
|
artikel
|
| 26 |
Quality assurance and cancer medicines in low-income and middle-income countries
|
Tuck, Chloe
|
|
|
22 |
3 |
p. 301-303
|
artikel
|
| 27 |
SARS-CoV-2 vaccination and phase 1 cancer clinical trials
|
Yap, Timothy A
|
|
|
22 |
3 |
p. 298-301
|
artikel
|
| 28 |
Short-term outcomes of complete mesocolic excision versus D2 dissection in patients undergoing laparoscopic colectomy for right colon cancer (RELARC): a randomised, controlled, phase 3, superiority trial
|
Xu, Lai
|
|
|
22 |
3 |
p. 391-401
|
artikel
|
| 29 |
The elusive pursuit of progress in limited stage small-cell lung cancer
|
Senan, Suresh
|
|
|
22 |
3 |
p. 290-291
|
artikel
|
| 30 |
The impact of the COVID-19 pandemic on radiotherapy services in England, UK: a population-based study
|
Spencer, Katie
|
|
|
22 |
3 |
p. 309-320
|
artikel
|
| 31 |
The role of radiotherapy in patients with solid tumours after solid organ transplantation: a systematic review
|
Mazzola, Rosario
|
|
|
22 |
3 |
p. e93-e104
|
artikel
|
| 32 |
The World Cancer Declaration: time to consolidate wins and work towards 2025
|
Johnson, Sonali
|
|
|
22 |
3 |
p. 296-298
|
artikel
|
| 33 |
Treatment of multiple myeloma-related bone disease: recommendations from the Bone Working Group of the International Myeloma Working Group
|
Terpos, Evangelos
|
|
|
22 |
3 |
p. e119-e130
|
artikel
|
| 34 |
Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group
|
Moreau, Philippe
|
|
|
22 |
3 |
p. e105-e118
|
artikel
|
| 35 |
Undruggable KRAS—time to rebrand?
|
The Lancet Oncology,
|
|
|
22 |
3 |
p. 289
|
artikel
|
| 36 |
Yale Cancer Center Precision Medicine Tumor Board: molecular findings alter a diagnosis and treatment plan
|
Gibson, Joanna A
|
|
|
22 |
3 |
p. 306-307
|
artikel
|
Tijdschrift beschrijving